Drug Trial Radar · NCT06858696
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Feb 28, 2025
Primary completion
Jan 12, 2026
Study completion Jan 12, 2026
Sponsor
- Lead sponsor
- X4 PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.
Conditions
- Hepatic Insufficiency
Interventions
MavorixaforDrug
Mavorixafor will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of MavorixaforTime frame: Predose up to 192 hours postdose (Day 1 up to Day 9)
- Area Under the Serum Concentration Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MavorixaforTime frame: Predose up to 192 hours postdose (Day 1 up to Day 9)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Catalina Research Institute, LLC
Montclair, California
Catalina Research Institute, LLC
Rialto, California
Orlando Clinical Research Center
Orlando, Florida
Texas Liver Institute/Alamo Medical Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.